Baiyunshan Subsidiary's Citicoline Sodium Injection Passes Consistency Evaluation and Adds New Specification

Regulation
โดย Jiemian·CN·Read original
Summary · why it matters

Baiyunshan announced that its controlling subsidiary Tianxin Pharmaceutical's Citicoline Sodium Injection in the 2ml:0.25g specification has passed the generic drug quality and efficacy consistency evaluation. At the same time, it received approval to add a new 4ml:0.5g specification, which is deemed to have passed the consistency evaluation. The drug is used for consciousness disorders following acute craniocerebral trauma and brain surgery.

Impact on stocks 1

Others▲ · 1 stocks

Off-coverage companies 1

广州白云山天心制药股份有限公司Private± Mixed
relevance

© 2026 MarketDXNews